Bringing p53 into the Clinic
- *Corresponding Author:
- Chit Fang Cheok
Principal Investigator IFOM, IFOMp53Lab Joint Research Laboratory
IFOM The FIRC Institute of Molecular Oncology Foundation
8A Biomedical Grove IMB Immunos #06-36, 138648, Singapore
E-mail: [email protected]; [email protected]
Received date: August 15, 2014; Accepted date: September 15, 2014; Published date: September 19, 2014
Citation: Tan EY, Cheok CF (2014) Bringing p53 into the Clinic. J Cancer Sci Ther 6:363-369. doi:10.4172/1948-5956.1000294
Copyright: © 2014 Tan EY, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The use of p53 as a biological marker to predict chemotherapeutic outcome has been challenging, with clinical research showing positive as well as negative correlations with p53 mutations. Recent research reveals the complexity that underlies the use of p53 as a single predictive marker as well as the challenges associated with classifying p53 mutations. It is becoming clear that various p53 mutations are associated with differential treatment response and outcomes. In addition, different drug regimens could also play a role in modifying the effects of p53 mutations on therapeutic outcome. Finally, we discuss improvements in the diagnostic detection of p53 mutations and gene signatures that may better reflect p53 functionality in tumors, which may serve as a more reliable tool in correlating p53 mutations to clinical response.